Sanofi US News
WEB2 days ago · Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through Dupixent, a first-in-class biologic, and the investigation of itepekimab.
Press Release: Dupixent approved in the US as the first-ever
WEBSep 27, 2013 · The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Dupixent is the first biologic medicine approved in the US to treat these patients.
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
WEB2 days ago · Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA) and Regeneron's (REGN.O) blockbuster drug Dupixent for patients with a chronic lung disease, commonly...
Sanofi blockbuster drug wins clearance in US for lung disease
WEB2 days ago · Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after a similar decision by European regulators.
Press Room - Sanofi US News
WEBSep 11, 2024 · A Dupixent (dupilumab) confirmatory phase 3 study (LIBERTY-CUPID Study C) met the primary and key secondary endpoints for the investigational treatment of patients with uncontrolled, biologic-naïve CSU receiving background therapy …
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
WEB2 days ago · Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. The approval brings the versatile drug’s count of U.S. indications up to six,...
Blockbuster Dupixent wins FDA approval for COPD - STAT
WEB2 days ago · Dupixent is already a blockbuster therapy for a range of immune-mediated diseases, but the Food and Drug Administration’s approval of the drug for chronic obstructive pulmonary disease greatly...
FDA, after delay, clears Regeneron and Sanofi drug for COPD
WEB2 days ago · The Food and Drug Administration on Friday approved Regeneron Pharmaceuticals and Sanofi’s inflammatory disease drug Dupixent for a common lung disease. The decision could significantly expand use of what is already one of the industry’s best-selling medicines.
Sanofi and Regeneron Biologic Drug Dupixent Notches a New …
WEB8 hours ago · Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers.
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic …
WEB2 days ago · (RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved Dupixent as an add-on maintenance treatment of...
Skip to content